Avricore Health Corporate Update: Effective Plan, Resources Result in Success
29 nov. 2024 07h30 HE
|
Avricore Health Inc.
Avricore Health Inc. (AVCR) releases its third-quarter results.
Avricore Health Recognized in Deloitte’s 2024 Technology Fast 50™ Companies to Watch
06 nov. 2024 15h14 HE
|
Avricore Health Inc.
Avricore earned 8th spot in Deloitte Canada’s 2024 Technology Fast 50™ Companies-to-Watch list, reflecting its significant growth.
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
18 déc. 2023 07h30 HE
|
POINT Biopharma
BEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced...
Avricore Health Corporate Update – Company Demonstrates Strong Growth
30 nov. 2023 12h58 HE
|
Avricore Health Inc.
Avricore Health provides a corporate update and results for the first 9 months of 2023.
HealthTab™ Signs Reseller Agreement With Abbott to Support UK Expansion
08 août 2023 11h54 HE
|
Avricore Health Inc.
VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce the signing of a reseller...
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
26 juin 2023 07h45 HE
|
POINT Biopharma
INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and...
Avricore Health Hosts 2023 Annual General Meeting and Welcomes New Board Members
21 juin 2023 18h38 HE
|
Avricore Health Inc.
VANCOUVER, British Columbia, June 21, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) held its annual general meeting to elect directors, appoint its auditor and...
POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
25 mai 2023 08h30 HE
|
POINT Biopharma
PNT2004 program’s phase 1 FRONTIER trial design to be presented Abstract to be released today at 5:00 PM ET, May 25th Poster to be available starting at 9:00 AM ET, June 3rd INDIANAPOLIS, May 25,...
POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer
15 mai 2023 07h35 HE
|
POINT Biopharma
INDIANAPOLIS and LANSING, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global...
Avricore Health Corporate Updates on Audited Results for 2022
02 mai 2023 07h30 HE
|
Avricore Health Inc.
VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) today is pleased to announce its audited final results for 2022. ...